Search Result

Results for "

repolarization

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (1) Arrestin (1) Autophagy (7) Bacterial (7) Calcium Channel (1) Complement System (2) Cytochrome P450 (1) Drug Metabolite (1) ERK (1) Eukaryotic Initiation Factor (eIF) (1) HMG-CoA Reductase (HMGCR) (7) Integrin (1) Isotope-Labeled Compounds (4) JNK (1) Opioid Receptor (1) Parasite (2) Potassium Channel (18) Reference Standards (2) Serotonin Transporter (1) Sodium Channel (4) TNF Receptor (1) Transmembrane Glycoprotein (1)
By Research Areas:	Cancer (12) Cardiovascular Disease (19) Infection (3) Inflammation/Immunology (3) Metabolic Disease (7) Neurological Disease (2)

By Targets:

Apoptosis (1)

Arrestin (1)

Autophagy (7)

Bacterial (7)

Calcium Channel (1)

Complement System (2)

Cytochrome P450 (1)

Drug Metabolite (1)

ERK (1)

Eukaryotic Initiation Factor (eIF) (1)

HMG-CoA Reductase (HMGCR) (7)

Integrin (1)

Isotope-Labeled Compounds (4)

JNK (1)

Opioid Receptor (1)

Parasite (2)

Potassium Channel (18)

Reference Standards (2)

Serotonin Transporter (1)

Sodium Channel (4)

TNF Receptor (1)

Transmembrane Glycoprotein (1)

By Research Areas:

Cancer (12)

Cardiovascular Disease (19)

Infection (3)

Inflammation/Immunology (3)

Metabolic Disease (7)

Neurological Disease (2)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-17504

Rosuvastatin Calcium Maximum Cited Publications 24 Publications Verification Rosuvastatin hemicalcium; ZD 4522 Calcium	HMG-CoA Reductase (HMGCR) Autophagy Potassium Channel Bacterial	Cardiovascular Disease Metabolic Disease Cancer
Rosuvastatin Calcium is a competitive HMG-CoA reductase (HMGCR) inhibitor, with an IC₅₀ of 11 nM. Rosuvastatin Calcium potently blocks hERG current with an IC₅₀ of 195 nM . Rosuvastatin Calcium reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin Calcium effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .

HY-17504A

Rosuvastatin Maximum Cited Publications 24 Publications Verification ZD 4522	HMG-CoA Reductase (HMGCR) Autophagy Potassium Channel Bacterial	Cardiovascular Disease Metabolic Disease Cancer
Rosuvastatin (ZD 4522) is a competitive HMG-CoA reductase inhibitor with an IC₅₀ of 11 nM. Rosuvastatin potently blocks hERG current with an IC₅₀ of 195 nM, delayed cardiac repolarization, and thereby prolonged action potential durations (APDs) and corrected QT interval (QTc) intervals. Rosuvastatin reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .

HY-17504B

Rosuvastatin Sodium Maximum Cited Publications 24 Publications Verification ZD 4522 Sodium; X-Plended Sodium; Crestor Sodium	HMG-CoA Reductase (HMGCR) Potassium Channel Autophagy Bacterial	Cardiovascular Disease Metabolic Disease Cancer
Rosuvastatin Sodium is a competitive HMG-CoA reductase (HMGCR) inhibitor, with an IC₅₀ of 11 nM. Rosuvastatin Sodium potently blocks hERG current with an IC₅₀ of 195 nM . Rosuvastatin Sodium reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin Sodium effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .

HY-15701B

ADH-503 2 Publications Verification (Z)-Leukadherin-1 choline	Complement System	Cancer
ADH-503 ((Z)-Leukadherin-1 choline) is an orally active and allosteric CD11b agonist. ADH-503 leads to the repolarization of tumor-associated macrophages, reduction in the number of tumor-infiltrating immunosuppressive myeloid cells, and enhances dendritic cell responses .

HY-111747

TBAJ-587 3 Publications Verification	Bacterial	Infection Cardiovascular Disease
TBAJ-587, a potent anti-tuberculosis agent, inhibits M.tb strain H37Rv growth with MIC₉₀s of 0.006 and <0.02 μg/mL in MABA and LORA assay, respectively. TBAJ-587 inhibits hERG channel minimally, attenuates inhibition of the cardiac potassium channel protein coded by the hERG, which is important for cardiac repolarization .

HY-16738A

Eleclazine hydrochloride 2 Publications Verification GS 6615 hydrochloride	Sodium Channel Potassium Channel	Cardiovascular Disease
Eleclazine (GS 6615) hydrochloride is a selective cardiac late sodium current inhibitor and a weak inhibitor of potassium current with IC₅₀ value of <1 μM and approximately 14.2 μM, respectively. Eleclazine hydrochloride shows concurrent protection against autonomically induced atrial premature beats, repolarization alternans and heterogeneity, and atrial fibrillation in porcine model. Eleclazine hydrochloride can be used to research cardiac arrhythmias .

HY-136832

Noribogaine hydrochloride	Serotonin Transporter Potassium Channel Arrestin Opioid Receptor	Cardiovascular Disease Neurological Disease
Noribogaine hydrochloride is an orally active, blood-brain barrier permeable SERT inhibitor (IC₅₀=50-300 nM) and hERG channel blocker. Noribogaine hydrochloride enhances serotonergic transmission, activates the κ-opioid receptor (OPRK) G protein signaling pathway and inhibits β-arrestin recruitment. Meanwhile, Noribogaine hydrochloride blocks the μ-opioid receptor (OPRM) signaling pathway as well as ion channels associated with cardiac repolarization. Noribogaine hydrochloride induces neuritogenesis, upregulates GDNF mRNA expression, and modulates opioid tolerance. Noribogaine hydrochloride reduces alcohol-seeking behavior in experimental animals, and is widely used in studies related to depression, addiction, alcoholism, and cardiotoxicity .

HY-124702

ICA-105574 1 Publications Verification	Potassium Channel	Cardiovascular Disease
ICA-105574 is a potent and efficacious hERG channel activator. The primary mechanism by which ICA-105574 potentiates hERG channel activity is by removing hERG channel inactivation. ICA-105574 steeply potentiates current amplitudes more than 10-fold with an EC₅₀ value of 0.5 +/- 0.1 μM and a Hill slope (n(H)) of 3.3 +/- 0.2. ICA-105574 can prevent arrhythmias induced by cardiac delayed repolarization. ICA-105574 shortens action potential duration in ventricular myocytes concentration-dependently .

HY-12082A

GSK369796 Dihydrochloride	Potassium Channel Parasite	Infection
GSK369796 Dihydrochloride is an affordable and effective antimalarial and inhibits hERG potassium ion channel repolarization with an IC₅₀ of 7.5 μM.

HY-101253

AM-92016 hydrochloride 1 Publications Verification	Potassium Channel	Cardiovascular Disease
AM-92016 hydrochloride is a specific blocker of rectifier potassium current (IK). AM-92016 hydrochloride delays rectifier potassium channel (IK), repolarizes the membrane thereby restricting the duration of the nerve impulse thereby restricting the duration of the nerve impulse .

HY-P11107

RP-832c	Apoptosis TNF Receptor	Inflammation/Immunology Cancer
RP-832c is a synthetic analogue of host defense peptides (HDP), targeting the mannose receptor CD206 on the surface of M2 polarized macrophages (K_d = 3.5 μM). RP-832c binding to CD206 induces a significant conformational change in the receptor, activating signaling pathways that lead to rapid apoptosis and repolarization of CD206-positive M2 macrophages to an M1 phenotype. RP-832c treatment significantly reduces CD206 gene expression in M2 macrophages while transiently increasing expression of TNF-α, a marker for M1 macrophages. RP-832c is used for the studies of T-cell lymphoma (CTCL) and idiopathic pulmonary fibrosis (IPF) .

HY-17504AS1

Rosuvastatin-d6 ZD 4522-d₆	Isotope-Labeled Compounds Autophagy Bacterial HMG-CoA Reductase (HMGCR) Potassium Channel	Cardiovascular Disease Metabolic Disease Cancer
Rosuvastatin-d₆ (ZD 4522-d₆) is deuterium labeled Rosuvastatin. Rosuvastatin (ZD 4522) is a competitive HMG-CoA reductase inhibitor with an IC₅₀ of 11 nM. Rosuvastatin potently blocks hERG current with an IC₅₀ of 195 nM, delayed cardiac repolarization, and thereby prolonged action potential durations (APDs) and corrected QT interval (QTc) intervals. Rosuvastatin reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .

HY-163642

TNF-α agonistic 1	Others	Cancer
TNF-α agonistic 1 (compound 22a) can repolarize tumor-associated macrophages (TAMs) in the tumor microenvironment (TME) from the M2 phenotype to the M1 anti-tumor phenotype .

HY-17504AS

Rosuvastatin-d3 ZD 4522 d₃	Isotope-Labeled Compounds HMG-CoA Reductase (HMGCR) Autophagy Potassium Channel	Cardiovascular Disease Metabolic Disease
Rosuvastatin-d₃ (ZD 4522-d₃) is a deuterium labeled Rosuvastatin. Rosuvastatin (ZD 4522) is a competitive HMG-CoA reductase inhibitor with an IC₅₀ of 11 nM . Rosuvastatin potently blocks human ether-a-go-go related gene (hERG) current with an IC₅₀ of 195 nM, delayed cardiac repolarization, and thereby prolonged action potential durations (APDs) and corrected QT interval (QTc) intervals .

HY-B0615AS

Moricizine-d8Hydrochloride EN 313-d₈; Ethmozin-d₈; Moracizine-d₈	Isotope-Labeled Compounds	Cardiovascular Disease
Moricizine-d₈ Hydrochloride is the deuterium labeled Moricizine Hydrochloride (HY-B0615A). Moricizine Hydrochloride is an orally active Class I antiarrhythmic agent. Moricizine Hydrochloride decreases the maximum rate of phase 0 depolarization; increases rates of phase 2 and 3 repolarization, decreases action potential duration, and decreases effective refractory period .

HY-16738

Eleclazine 2 Publications Verification GS-6615	Sodium Channel Potassium Channel	Cardiovascular Disease
Eleclazine (GS 6615) is a selective cardiac late sodium current inhibitor and a weak inhibitor of potassium current with IC₅₀ of <1 μM and approximately 14.2 μM, respectively. Eleclazine shows concurrent protection against autonomically induced atrial premature beats, repolarization alternans and heterogeneity, and atrial fibrillation in porcine model. Eleclazine can be used to research cardiac arrhythmias .

HY-175288

αMβ2 integrin agonist-1	Integrin JNK ERK	Inflammation/Immunology Cancer
αMβ2 integrin agonist-1 (Compound 8) is a highly selective αMβ2 integrin agonist with anti-inflammatory activity (EC₅₀=1.4 nM). αMβ2 integrin agonist-1 activates integrin-mediated cell adhesion and JNK/ERK signaling. αMβ2 integrin agonist-1 induces tumor-associated macrophage repolarization and enhances antitumor T-cell immune responses. αMβ2 integrin agonist-1 is promising for research of cancers and chronic inflammatory diseases (e.g., pancreatic cancer, rheumatoid arthritis) .

HY-P991181

VTX-1218	Transmembrane Glycoprotein	Cancer
VTX-1218 is a VSIG4 inhibitor with human K_d 7.4 nM. VTX-1218 blocks VSIG4 activity, relieves VSIG4-mediated macrophage suppression, repolarizes tumor-associated macrophages and induces T cell activation. VTX-1218 upregulates cytokines and chemokines linked to immune cell recruitment. VTX-1218 can be used for the research of multiple cancer types .

HY-17504BR

Rosuvastatin Sodium (Standard) ZD 4522 Sodium (Standard); X-Plended Sodium (Standard); Crestor Sodium (Standard)	HMG-CoA Reductase (HMGCR) Potassium Channel Autophagy Bacterial Reference Standards	Cardiovascular Disease Metabolic Disease Cancer
Rosuvastatin (Sodium) (Standard) is the analytical standard of Rosuvastatin (Sodium). This product is intended for research and analytical applications. Rosuvastatin Sodium is a competitive HMG-CoA reductase (HMGCR) inhibitor, with an IC50 of 11 nM. Rosuvastatin Sodium potently blocks hERG current with an IC50 of 195 nM . Rosuvastatin Sodium reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin Sodium effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .

HY-17504BS2

Rosuvastatin-13C,d3 sodium ZD 4522-13C,d3 sodium; X-Plended-13C,d3 sodium; Crestor-13C,d3 sodium	Autophagy Bacterial HMG-CoA Reductase (HMGCR) Potassium Channel Isotope-Labeled Compounds	Cardiovascular Disease Metabolic Disease
Rosuvastatin- ¹³C,d₃ sodium is ¹³C and deuterated labeled Rosuvastatin sodium (HY-17504B). Rosuvastatin Sodium is a competitive HMG-CoA reductase (HMGCR) inhibitor, with an IC₅₀ of 11 nM. Rosuvastatin Sodium potently blocks hERG current with an IC₅₀ of 195 nM . Rosuvastatin Sodium reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin Sodium effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .

HY-15701A

(Z)-Leukadherin-1 2 Publications Verification ADH-503 free base	Complement System	Cancer
(Z)-Leukadherin-1 (ADH-503 free base) is an orally active and allosteric CD11b agonist. (Z)-Leukadherin-1 leads to the repolarization of tumor-associated macrophages, reduction in the number of tumor-infiltrating immunosuppressive myeloid cells, and enhances dendritic cell responses .

HY-12082

GSK369796	Potassium Channel Parasite	Infection
GSK369796 is an affordable and effective antimalarial and inhibits hERG potassium ion channel repolarization with an IC₅₀ of 7.5 μM .

HY-B0615A

Moricizine Hydrochloride EN 313; Ethmozin; Moracizine	Cytochrome P450	Cardiovascular Disease
Moricizine Hydrochloride (EN 313) is an orally active Class I antiarrhythmic agent. Moricizine Hydrochloride decreases the maximum rate of phase 0 depolarization; increases rates of phase 2 and 3 repolarization, decreases action potential duration, and decreases effective refractory period .

HY-113673

A-935142	Potassium Channel	Cardiovascular Disease
A-935142 is a human ether-a-go-go-related gene (hERG, Kv 11.1) channel activator. A-935142 enhances hERG current in a complex manner by facilitation of activation, reduction of inactivation, and slowing of deactivation, and abbreviates atrial and ventricular repolarization .

HY-12773A

5-Hydroxy Propafenone hydrochloride GPV-129 hydrochloride	Drug Metabolite	Cardiovascular Disease
5-Hydroxy Propafenone (hydrochloride) is an inhibitor of *cardiac myocyte repolarizing* currents. 5-Hydroxy Propafenone is an active metabolite of propafenone. 5-Hydroxy Propafenone (hydrochloride) inhibits transient outward potassium current (Ito) in isolated human arterial myocytes with an IC₅₀** of 1.5 μM. 5-Hydroxy Propafenone (hydrochloride) is potent Ito inhibitor in neonatal rat ventricular myocytes .

HY-W705705

NIP 142	Calcium Channel Potassium Channel Sodium Channel	Cardiovascular Disease
NIP-142 is a benzopyran derivative with multiple ion channel-blocking effects. NIP-142 selectively blocks the potassium ion channels enriched in atrial muscle, prolonging the effective refractory period (ERP) and action potential duration (APD) of the atrium, while having minimal effect on ventricular repolarization. NIP-142 also inhibits L-type/T-type calcium channels and sodium channels, further contributing to its anti-arrhythmic effect. NIP-142 shows significant efficacy in various atrial fibrillation models. NIP-142 can be used for research on arrhythmias .

HY-16738AR

Eleclazine hydrochloride (Standard) GS 6615 hydrochloride (Standard)	Sodium Channel Potassium Channel Reference Standards	Cardiovascular Disease
Eleclazine (hydrochloride) (Standard) is the analytical standard of Eleclazine (hydrochloride). This product is intended for research and analytical applications. Eleclazine (GS 6615) hydrochloride is a selective cardiac late sodium current inhibitor and a weak inhibitor of potassium current with IC50 value of <1 μM and approximately 14.2 μM, respectively. Eleclazine hydrochloride shows concurrent protection against autonomically induced atrial premature beats, repolarization alternans and heterogeneity, and atrial fibrillation in porcine model. Eleclazine hydrochloride can be used to research cardiac arrhythmias .

HY-181406

eIF2B activator-1	Eukaryotic Initiation Factor (eIF) Potassium Channel	Neurological Disease
eIF2B activator-1 (Compound 7a) is a eIF2B activator with a pEC₅₀ value of 7.3. eIF2B activator-1 exhibits significant hERG inhibitory activity, with a pIC₅₀ value of 5.7. eIF2B activator-1 can be used in research related to Huntington's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS).

Cat. No.	Product Name	Target	Research Area

HY-P10449

M2 Peptide	Peptides	Inflammation/Immunology Cancer
M2 Peptide is a peptide targeting M2-like tumor-associated macrophages (TAMs). M2 Peptide is used to carry drugs or small interfering RNA (siRNA) to promote the repolarization of M2-like macrophages to M1-like macrophages, thereby altering the immunosuppressive state in the tumor microenvironment and enhancing the anti-tumor immune response. M2 Peptide can be used to study the effect of macrophage polarization and how this polarization change affects tumor growth and metastasis .

HY-P11107

RP-832c	Apoptosis TNF Receptor	Inflammation/Immunology Cancer
RP-832c is a synthetic analogue of host defense peptides (HDP), targeting the mannose receptor CD206 on the surface of M2 polarized macrophages (K_d = 3.5 μM). RP-832c binding to CD206 induces a significant conformational change in the receptor, activating signaling pathways that lead to rapid apoptosis and repolarization of CD206-positive M2 macrophages to an M1 phenotype. RP-832c treatment significantly reduces CD206 gene expression in M2 macrophages while transiently increasing expression of TNF-α, a marker for M1 macrophages. RP-832c is used for the studies of T-cell lymphoma (CTCL) and idiopathic pulmonary fibrosis (IPF) .

Cat. No.	Product Name	Target	Research Area	Image

HY-P991181

VTX-1218	Transmembrane Glycoprotein	Cancer
VTX-1218 is a VSIG4 inhibitor with human K_d 7.4 nM. VTX-1218 blocks VSIG4 activity, relieves VSIG4-mediated macrophage suppression, repolarizes tumor-associated macrophages and induces T cell activation. VTX-1218 upregulates cytokines and chemokines linked to immune cell recruitment. VTX-1218 can be used for the research of multiple cancer types .

Cat. No.	Product Name	Chemical Structure

HY-17504AS1

Rosuvastatin-d6
Rosuvastatin-d₆ (ZD 4522-d₆) is deuterium labeled Rosuvastatin. Rosuvastatin (ZD 4522) is a competitive HMG-CoA reductase inhibitor with an IC₅₀ of 11 nM. Rosuvastatin potently blocks hERG current with an IC₅₀ of 195 nM, delayed cardiac repolarization, and thereby prolonged action potential durations (APDs) and corrected QT interval (QTc) intervals. Rosuvastatin reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .

Rosuvastatin-d6

Rosuvastatin-d₆ (ZD 4522-d₆) is deuterium labeled Rosuvastatin. Rosuvastatin (ZD 4522) is a competitive HMG-CoA reductase inhibitor with an IC₅₀ of 11 nM. Rosuvastatin potently blocks hERG current with an IC₅₀ of 195 nM, delayed cardiac repolarization, and thereby prolonged action potential durations (APDs) and corrected QT interval (QTc) intervals. Rosuvastatin reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .

HY-17504AS

Rosuvastatin-d3
Rosuvastatin-d₃ (ZD 4522-d₃) is a deuterium labeled Rosuvastatin. Rosuvastatin (ZD 4522) is a competitive HMG-CoA reductase inhibitor with an IC₅₀ of 11 nM . Rosuvastatin potently blocks human ether-a-go-go related gene (hERG) current with an IC₅₀ of 195 nM, delayed cardiac repolarization, and thereby prolonged action potential durations (APDs) and corrected QT interval (QTc) intervals .

Rosuvastatin-d3

Rosuvastatin-d₃ (ZD 4522-d₃) is a deuterium labeled Rosuvastatin. Rosuvastatin (ZD 4522) is a competitive HMG-CoA reductase inhibitor with an IC₅₀ of 11 nM . Rosuvastatin potently blocks human ether-a-go-go related gene (hERG) current with an IC₅₀ of 195 nM, delayed cardiac repolarization, and thereby prolonged action potential durations (APDs) and corrected QT interval (QTc) intervals .

HY-B0615AS

Moricizine-d8Hydrochloride
Moricizine-d₈ Hydrochloride is the deuterium labeled Moricizine Hydrochloride (HY-B0615A). Moricizine Hydrochloride is an orally active Class I antiarrhythmic agent. Moricizine Hydrochloride decreases the maximum rate of phase 0 depolarization; increases rates of phase 2 and 3 repolarization, decreases action potential duration, and decreases effective refractory period .

HY-17504BS2

Rosuvastatin-13C,d3 sodium
Rosuvastatin- ¹³C,d₃ sodium is ¹³C and deuterated labeled Rosuvastatin sodium (HY-17504B). Rosuvastatin Sodium is a competitive HMG-CoA reductase (HMGCR) inhibitor, with an IC₅₀ of 11 nM. Rosuvastatin Sodium potently blocks hERG current with an IC₅₀ of 195 nM . Rosuvastatin Sodium reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin Sodium effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .

Rosuvastatin-13C,d3 sodium

Rosuvastatin- ¹³C,d₃ sodium is ¹³C and deuterated labeled Rosuvastatin sodium (HY-17504B). Rosuvastatin Sodium is a competitive HMG-CoA reductase (HMGCR) inhibitor, with an IC₅₀ of 11 nM. Rosuvastatin Sodium potently blocks hERG current with an IC₅₀ of 195 nM . Rosuvastatin Sodium reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin Sodium effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: